Abstract: Dosage forms and methods for the controlled release of oxycodone over a prolonged period of time are described. The sustained release dosage forms provide therapeutically effective average steady-state plasma oxycodone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma oxycodone concentration occurrence in each 24 hour period that occurs at a later time after administration and exhibits a lesser magnitude than the peak plasma oxycodone concentration that occurs following administration of oxycodone in an immediate-release dosage form and other prior art extended release dosage forms.

Abstract: Described herein are vascular endothelial cell growth factor (VEGF) variants having structural alterations in the C-terminus heparin binding domain and methods of use. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.